For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  ARA-290 (Cibinetide)
Immuneearly_human

ARA-290 (Cibinetide)

Cibinetide
Immune · CAS 1208243-50-8
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Immune
Evidence grade
C
PubMed records
34
Female-tagged
13
Sex-analysis
0
CAS
1208243-50-8
C
Evidence grade C, Early human data only (Phase 1 / small-n) across 34 indexed studies. How grades work →
Female evidence: Extrapolated
ARA-290 (Cibinetide): of 34 PubMed records, 13 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

ARA-290, also known as cibinetide, is a synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO). It was engineered to engage the innate repair receptor while lacking EPO's erythropoietic, or red-blood-cell-stimulating, activity, which gives it a research-friendly profile as a tool for separating tissue-protective signaling from hematopoietic effects.

In preclinical models ARA-290 has been studied for its relationship to the innate repair receptor and the tissue-protection and neuropathy pathways associated with it. Researchers examining EPO-derived signaling have used it as a research material to characterize how this non-hematopoietic fragment interacts with its target in cell-based and animal systems.

What makes ARA-290 a useful entry for a tissue-protection research catalog is the specificity of its designed target relative to native erythropoietin. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

ARA-290 (cibinetide) is a non-erythropoietic peptide derived from erythropoietin, studied in small Phase 2 trials for small-fiber neuropathy (including in sarcoidosis) and diabetic neuropathy. Trials enrolled women, but were not powered or designed for sex-specific analysis.

Evidence in women

Menstrual cycle
Unstudied
No study examined neuropathy or repair endpoints across the menstrual cycle.
Pregnancy & lactation
Unstudied
No pregnancy or lactation safety data from the trial program.
Hormonal interactions
Unstudied
No data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific analyses.
Sex differences
Unstudied
Small Phase 2 trials enrolled women but were underpowered for and did not report sex-specific outcomes.

Mechanism

Selectively activates the innate repair receptor (a heteromer of the EPO receptor and CD131) to reduce inflammation and support tissue repair without stimulating erythropoiesis.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)4 mg/day subcutaneous in Phase 2 neuropathy trials; investigational.
Routessubcutaneous
Female-specific dosingNot established

Contraindications: insufficient data to characterize

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

generally well tolerated in trials

ARA-290 (Cibinetide) reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for ARA-290 (Cibinetide)

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from ARA-290 (Cibinetide)'s research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is ARA-290 (Cibinetide)?

ARA-290 (Cibinetide), also known as Cibinetide, is a research compound in our immune category. ARA-290 (cibinetide) is a non-erythropoietic peptide derived from erythropoietin, studied in small Phase 2 trials for small-fiber neuropathy (including in sarcoidosis) and diabetic neuropathy.

Is ARA-290 (Cibinetide) studied in women?

ARA-290 (Cibinetide): of 34 PubMed records, 13 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has ARA-290 (Cibinetide) been studied during pregnancy or breastfeeding?

Unstudied. No pregnancy or lactation safety data from the trial program. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does ARA-290 (Cibinetide) have, and why?

ARA-290 (Cibinetide) carries evidence grade C. Early human data only (Phase 1 / small-n) across 34 indexed studies.. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for ARA-290 (Cibinetide)?

No. A female-specific dose for ARA-290 (Cibinetide) is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is ARA-290 (Cibinetide) administered in research?

In the published literature, ARA-290 (Cibinetide) is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for ARA-290 (Cibinetide)?

Effects reported in the research literature include generally well tolerated in trials. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

What is the CAS number for ARA-290 (Cibinetide)?

The CAS registry number for ARA-290 (Cibinetide) is 1208243-50-8. It is also referred to as Cibinetide, ARA290. Use it to confirm identity against a Certificate of Analysis.

How should ARA-290 (Cibinetide) be stored and handled?

ARA-290 (Cibinetide) sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy ARA-290 (Cibinetide) for research?

For laboratory research use, ARA-290 (Cibinetide) is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy ARA-290 (Cibinetide) at Aurevena Research
Research-use supplier: ARA-290 (Cibinetide) is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Citations (PMID)

25728128 · 33423557 · 27507833

Related peptides

KPVD
KPV: of 47 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
LL-37D
LL-37: of 2,527 PubMed records, 501 are tagged as including female subjects and 2 carry a sex-analysis tag.
ThymalinD
Thymalin: of 234 PubMed records, 75 are tagged as including female subjects and 0 carry a sex-analysis tag.
ThymogenD
Thymogen: of 89 PubMed records, 26 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.